2 completed, 2 unknown, 1 recruiting, 1 terminated. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 2, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow CIN1: new trials by email Literature Review of CIN1 trials Research Report on CIN1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test Trichloroacetic acid - CIN1, Trichloroacetic Acid | Phase 2 / Phase 3 | Withdrawn | Department of Medical Services Ministry of Public Health of Thailand | 2023-11-30 | 2024-01-03 | |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart | Phase 3 | Terminated | Shanghai Bovax Biotechnology Co., Ltd. | 3131 | 2022-12-09 | 2023-07-21 |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1348 | 2021-09-15 | 2024-04-17 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years 9-valent HPV vaccine - HPV Infections, Cervical Cancer | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2021-05-28 | 2024-04-17 |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2020-09-19 | 2023-11-24 |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1680 | 2020-05-28 | 2022-02-25 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 8000 | 2020-04-28 | 2024-06-07 |
Condylomata Acuminata (6) · Uterine Cervical Neoplasms (6) · Vaginal Neoplasms (5) · Vulvar Neoplasms (4) · Papillomavirus Infections (3)
Communicable Diseases (6) · DNA Virus Infections (6) · Disease Attributes (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Infections (6) · Neoplasms (6) · Neoplasms by Site (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Sexually Transmitted Diseases (6) · Sexually Transmitted Diseases, Viral (6)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Vaccines, Synthetic (2) · Acetic Acid (1) · Trichloroacetic Acid (1)
Shanghai Bovax Biotechnology Co., Ltd. (6) · Department of Medical Services Ministry of Public Health of Thailand (1)
China (6) · Thailand (1)
Ting Huang (1)